HIGHLIGHTS
• Women with endometrial cancer are at risk of second primary cancers.
• Overall and anatomical site specific second primary cancer risk varies by endometrial cancer histology.
• Endometrial cancer clinicians should be aware of divergent secondprimary cancer risks associated with histology.
AbSTrACT
Objective To evaluate the risk of a second primary cancer after endometrial cancer according to histological subtype.
Methods Using data from the 13 National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) registries we identified women diagnosed with a primary endometrial cancer between 1992 and 2014. We calculated standardized incidence ratios (SIRs) and 95% confidence intervals (CIs) for second primary cancer risk (all anatomical sites combined and for individual anatomical sites) among patients with endometrial cancer compared with the general population, in the overall study population and according to histological subtype.
results Among 96 256 women diagnosed with endometrial cancer, 8.4% (n=8083) developed a second primary cancer. The risk of second primary cancer was higher among patients with endometrial cancer than in the general population (SIR=1.05, 95% CI 1.03 to 1.07). We observed significantly higher second primary cancer risk among women with high grade endometrioid (SIR=1.12, 95% CI 1.05 to 1.19) , serous (SIR=1.24, 95% CI 1.11 to 1.38), carcinosarcoma (SIR=1.18, 95% CI 1.02 to 1.35) , mixed epithelial (SIR=1.22, 95% CI 1.06 to 1.40), and sarcoma (SIR=1.28, 95% CI 1.12 to 1.45) compared with the general population, but not for women with low grade endometrioid (SIR=1.01, 95% CI 0.98 to 1.03) or clear cell (SIR=1.09, 95% CI 0.88 to 1.33) endometrial cancer. Women with low grade endometrioid endometrial cancer had significantly lower second primary cancer risks in the gum and other mouth (SIR=0.57, 95% CI 0.30 to 0.97), lung and bronchus (SIR=0.72, 95% CI 0.66 to 0.77), and lymphocytic leukemia (SIR=0.71, 95% CI 0.54 to 0.93) while women with high risk endometrial cancer histological subtypes experienced significantly higher second primary cancer risk at several anatomical sites.
Conclusions Risk of developing second primary cancersat all anatomic sites combined and at individual anatomical sites varied according to histological subtype. Clinicians should be aware that women with different histological subtypes carry different second primary cancer risks .
InTrOduCTIOn
Uterine cancer is the most common gynecological cancer in the USA and the fourth most common cancer overall in women. In 2018, 63 230 new cases are expected with an estimated 11 000 deaths. 1 Endometrial cancer comprises approximately 90% of all uterine cancers. Since 2000, the annual incidence of endometrial cancer has risen, mainly driven by increases in the prevalence of obesity. 2 Moreover, changes in the prevalence of other established risk factors, including increases in the incidence of diabetes, declining use of combination menopausal hormone use, and decreases in parity and smoking, have also contributed to recent increases in endometrial cancer incidence. Overall, the prognosis for women with endometrial cancer is favorable owing to the large proportion of cases detected when the disease is localized to the uterus. 3 With more women developing endometrial cancer and surviving the disease, long term health concerns, including the development of second primary cancers, are increasingly important.
There are conflicting reports on the association between an endometrial cancer diagnosis and the overall risk of developing a second primary cancer, possibly reflecting heterogeneous risks for particular anatomic sites. For instance, risks for second primary cancers in the colon, breast, bladder, and soft tissue are consistently elevated after endometrial cancer while risks for lung and esophageal cancers are usually lower among women with endometrial cancer compared with the general population. [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] These patterns of anatomic site specific second primary cancer risk probably reflect overlapping etiology, late effects of cancer treatment, and genetic susceptibility. 15 As an example, obesity is strongly related to the risk of developing endometrial, colon, and breast cancers, 16 and therefore, obese women who develop and survive their endometrial cancer are also at risk of developing other obesity related cancers.
Original Article
Endometrial cancer is recognized as etiologically heterogeneous, with notable differences in the magnitude of risk factor associations according to histological subtype. [17] [18] [19] As such, it is plausible that the risk and distribution of second primary cancers varies according to the primary endometrial cancer histological subtype. Additionally, histological subtype guides adjuvant treatment decisions, 20 resulting in differences in exposures to chemotherapy and/or radiation according to histological subtype. While patients with early stage, well differentiated endometrioid disease undergo surveillance or radiation, those with high risk histologies, such as serous, typically receive platinum based chemotherapy with or without radiation. 20 These treatment patterns could impact second primary cancer risk as chemotherapy and radiation are carcinogenic and have been shown to increase the risk of second primary cancers at various sites, including the colon and bladder, and leukemias. 15 21 Few studies have addressed the risk of developing a second primary cancer after endometrial cancer according to histological subtype. Understanding these patterns could provide further insights into the epidemiology of endometrial cancer and guide clinical decisions regarding surveillance and adjuvant treatment after endometrial cancer. We addressed this gap in the literature using data from the Surveillance, Epidemiology, and End Results (SEER) program, with diverse representation of endometrial cancer histological subtypes.
MeTHOdS data Source
The SEER database is the source of population based cancer information provided by the National Cancer Institute. For the current analysis, we used data from 13 SEER registries which include Atlanta, Connecticut, Detroit, Hawaii, Iowa, New Mexico, San Francisco-Oakland, Seattle-Puget Sound, and Utah. Information on all incident cancers (excluding basal or squamous cell skin cancer) occurring within these regions is collected by SEER.
Study Population
We included women ≥18 years of age at the time of a first primary endometrial cancer (C54.0-C54.9, C55.9) diagnosed between 1992 and 2014, without a history of malignant cancer before endometrial cancer (not including benign and borderline tumors of the brain and central nervous system), and women whose primary endometrial cancer was not identified by death certificate or autopsy only. We defined second primary cancer as a new cancer occurrence diagnosed more than 2 months from the time of endometrial cancer diagnosis not considered to be metastatic disease or recurrence of the first neoplasm.
We 18 19 Endometrioid and mucinous adenocarcinoma were further classified as low grade (well differentiated or moderately differentiated) or high grade (poorly differentiated, undifferentiated, or anaplastic) endometrioid. By definition, serous, carcinosarcoma, clear cell, mixed epithelial, and sarcoma histologies are considered poorly differentiated tumors; therefore, additional categorization based on grade was unnecessary. 22 
Statistical Analysis
We examined distributions of categorical variables related to the primary endometrial cancer diagnosis (age at diagnosis, race, calendar year of diagnosis, SEER registry, histology, grade, stage at diagnosis, surgical treatment status, radiation therapy, and chemotherapy) among all women with a first primary endometrial cancer and separately among patients with endometrial cancer who developed a second primary cancer.
Standardized incidence ratios (SIRs) were calculated for all women with a first diagnosis of endometrial cancer to determine risk associated with second primary cancer development. We used the Multiple Primary-Standardized Incidence Ratio program of the SEER*Stat software to calculate the SIRs for second primary cancer for all sites combined and for individual cancer sites. We excluded second cancers of the uterus, ovaries, and cervix from all analyses as endometrial cancer surgery typically involves removal of these organs, precluding development of cancers at these sites. SIRs were also calculated separately according to the primary endometrial cancer histological subtypes mentioned above. For each case group defined by the primary endometrial cancer histological subtype, we calculated SIRs for second primary cancers at all sites combined and for each of the most common non-endometrial cancer cancer sites. Follow-up time was counted from 2 months after the initial endometrial cancer diagnosis until the diagnosis of a second primary cancer, death, or end of the study (December 31, 2014). A single outcome analysis was used which caused individuals to exit the study when a second primary cancer or death occurred; thus, these individuals contributed no additional person time at risk. For each tumor site, the SIR was calculated with the following equation: observed number of cancer cases at a particular tumor site/expected number of cancer cases at that particular tumor site. 23 The observed number of cancer cases refers to the number of second primary cancers in this collection of registries. Expected numbers of second primary cancers were estimated by multiplying sex, race, age, and calendar year specific SEER cancer incidence rates (available at http:// seer. cancer. gov) by the accumulated person-years at risk.
All analyses were completed using SEER*Stat and SAS/STAT software (V.9.4 of the SAS System for Windows, SAS Institute, Cary, North Carolina, USA). This study was considered exempt by the institutional review board of the Ohio State University as all data are de-identified and intended for public use. All P values were two sided, and a P<0.05 was considered statistically significant.
reSuLTS

Study Population
Overall, 96 256 women with a primary endometrial cancer were included. Median age at the primary endometrial cancer diagnosis was 62 years (IQR 54-71). Eight per cent of women (n=8083) developed a second primary cancer, with a mean latency to Original Article development of second primary cancer of 7.1 years. Additional baseline characteristics of patients with primary endometrial cancer and among those who developed a second primary cancer are shown in Table 1 . The majority of women with a primary endometrial cancer were white (81.3%), with diagnoses of endometrioid tumors (80.7%) and localized stage disease (71.3%). Almost all women were treated with hysterectomy, 25% received radiation therapy, and approximately 13% received some type of chemotherapy. We observed approximately similar distributions of these variables among the subsets of patients with endometrial cancer who developed secondprimary cancers. Among women who did not develop second primary cancers, distributions were similar to all patients with endometrial cancer.
Second Primary Cancer risks in the Overall Study Population
Overall, we observed a significantly higher risk for the development of a second primary cancer at all anatomical sites combined comparing patients with endometrial cancer with the general population ( Figure 1) Several second primary cancer anatomical sites that were elevated in the overall analysis (eg, breast, myeloid and monocytic leukemia, lung, and bronchus) were only elevated for one histological subtype. For example, only women with low grade endometrioid endometrial cancer experienced a higher risk of second primary cancer of the breast (SIR=1.05, 95% CI 1.00 to 1.10) while women with carcinosarcoma had an elevated risk of myeloid and monocytic leukemia (SIR=3.03, 95% CI1.22 to 6.24).
Histology Specific Second Primary Cancer risks According to race, Stage, radiation, and Chemotherapy We examined endometrial cancer histology specific patterns of second primary cancer risk for all sites combined across strata defined by race, stage, radiation therapy, and chemotherapy (Figure 2A-D) . With a few exceptions, second primary cancer risk was higher among non-white patients with endometrial cancer compared with white cases, and among women with a regional or distant stage tumor than those with localized stages for all histological subtypes. Among women diagnosed with a primary endometrioid endometrial cancer, mixed epithelial, or sarcoma histology, radiation treatment was associated with a higher second primary cancer risk compared with no radiation treatment. Conversely, women with an index serous, carcinosarcoma, or clear cell histological subtype showed slightly higher second primary cancer risks when radiation treatment was not used. There were higher second primary cancer risks in women with endometrioid, carcinosarcoma, and sarcoma treated with chemotherapy compared with no chemotherapy.
dISCuSSIOn
This population based analysis adds to the existing body of literature related to endometrial cancer heterogeneity by demonstrating that second primary cancer risk varies according to the histological subtype of the primary endometrial cancer. Compared with the general population, overall second primary cancer risk was higher among women diagnosed with non-endometrioid histological subtypes, which carry a poor prognosis. Further, although the overall second primary cancer risk for women with low grade endometrioid 24 Further, we confirmed higher second primary cancer risks at specific anatomical sites, including the small intestine, breast, colon, kidney, and bladder 4-9 11-14 as well as elevated risks of soft tissue and acute non-lymphocytic leukemia second primary cancers. 6 11 Related to the breast second primary cancer finding, the risk we observed in the current analysis was lower in magnitude compared with prior studies, potentially reflecting the overall decline in breast cancer incidence that has been described since 2000. 25 Patterns of second primary cancer risk following an endometrial cancer diagnosis likely reflect several overlapping mechanisms, including shared risk or prevention factors, genetic predisposition, and treatment effects. 15 Analysis of histological subtype specific second primary cancers allows us to further comment on the potential for these mechanisms to contribute to second primary cancers after endometrial cancer. For example, our observation that lung/bronchus and esophageal second primary cancers were significantly lower among women with low grade endometrioid endometrial cancer is likely related to the well established link between cigarette smoking and decreased risk of endometrial cancer, particularly of the endometrioid type. 18 26 Similarly, increased risks of colorectal second primary cancer following low and high grade endometrioid and clear cell ECs could partially be related to obesity. 18 27 Heritable causes could also underlie links between endometrial cancer and increased risk of subsequent cancers, particularly colorectal, ovarian, bladder, and small intestine cancers, as risk of these malignancies is elevated among individuals with Lynch syndrome, a familial disorder caused by mutations in DNA mismatch repair genes. 28 Although Lynch syndrome confers a high absolute risk of cancer development, the low frequency of highly penetrant mutations in Lynch syndrome genes likely accounts for a small proportion of second primary cancers. 15 Treatment effects may also contribute to the observed patterns of second primary cancer risk. Adjuvant radiation therapy and chemotherapy are commonly prescribed to women diagnosed with high risk endometrial cancer histologies (eg, serous, clear cell, mixed epithelial, carcinosarcoma, and sarcomas) and could contribute to higher second primary cancer risk among these women. 12 20 Radiation induced second cancers can arise through perturbation of healthy tissue within the field of radiation. 29 In particular, increased risks of leukemia, colon, rectum, vulva, skin, and bladder second primary cancers among patients with endometrial cancer receiving radiation therapy have been observed, 30 particularly when women are younger at diagnosis. 31 In our analysis, we observed higher risks of leukemias and bladder second primary cancers among women with high grade endometrioid endometrial cancer or carcinosarcoma and higher colorectal second primary cancers following diagnosis of high grade endometrioid, serous, clear cell, and mixed epithelial tumors, in line with potential radiation effects. However, others have not observed radiation related increases in second primary cancers after endometrial cancer. In the Post-Operative Radiation Therapy in Endometrial Carcinoma I trial, 10 year rates of second primary cancers did not differ between patients with endometrial cancer who received external beam radiotherapy compared with those who did not receive radiation (17.3% versus 16.9%, respectively). 32 Inconsistencies in the literature are likely driven by variable radiation doses and use of intensity modulation radiation therapy as well as differences in follow-up procedures, patient populations, and the absence of stratification by second primary cancer anatomical site or histology of the primary endometrial cancer. Of note, Berrington de Gonzalez and colleagues 33 demonstrated a 14% higher risk of adult second primary cancers among women with primary endometrial cancer who received radiation compared with women who did not.
Chemotherapy is also associated with increased second primary cancer risk. Currently, platinum containing regimens, particularly carboplatin, are preferred for patients with endometrial cancer Original Article Original Article Figure 1 Standardized incidence ratios (SIRs) and 95% CIs for second primary cancer (SPC) risk overall and by latency. The figure shows a significantly higher risk for the development of an SPC at all anatomical sites combined comparing patients with endometrial cancer (EC) with the general population. The risk of SPC was highest within the 1year interval after EC diagnosis and decreased with increasing time since EC diagnosis.
undergoing chemotherapy. 20 In our study, if patients received chemotherapy they most likely received cisplatin due to the years of diagnosis included in the analysis. While a recent meta-analysis did not show an increased odds of overall second primary cancer among patients receiving cisplatin, there was a trend towards increased odds of secondary leukemias or myelodysplastic syndromes, in line with our observations of higher rates of several types of leukemias overall and for certain histological subtypes. 34 Few other studies have examined second primary cancer risk according to the histological subtype of the primary endometrial cancer. Hinshaw and colleagues explored site specific second primary cancers among women diagnosed with serous or clear cell endometrial cancer. 13 Increased risks of colorectal, renal, bladder, acute myeloid leukemia, and soft tissue second primary cancers were observed among serous endometrial cancer patients (n=8045), whereas women with clear cell endometrial cancer (n=1740) did not experience an increased risk of a second primary cancer at any anatomical site. Chen and colleagues 24 recently examined anatomical site specific second primary cancers according to endometrial cancer histological subtype among German and Swedish patients. They observed increased lung and ovarian second primary cancers among women with endometrioid endometrial cancer, increased cervical and kidney second primary cancers after clear cell endometrial cancer, and no increased risk of any second primary cancer following a serous endometrial cancer diagnosis. Our histology specific endometrial cancer findings contrast with this scant literature; however, differences in treatment or the underlying study populations may underpin dissimilar results.
The major strength of this analysis is the consideration of second primary cancer risks according to endometrial cancer histological subtypes, given differences in etiology, molecular aberrations, and recommended treatment. Additionally, we included a large sample size and a multi-institutional population representative of the US. Limitations of this study are related to the data available within the SEER program. For example, the SEER program does not collect detailed information regarding dose of radiation, type of chemotherapy, lifestyle factors, family history of cancer, or genetic factors, and thus our commentary on the etiology of second primary cancers in patients with endometrial cancer is speculative. Further, no central pathology review was conducted which could result in misclassification of endometrial cancer histological subtype, particularly for the non-endometrioid subtypes where poor intraobserver reproducibility has been reported. 35 Finally, we cannot rule out that some second primary cancers-particularly vaginal cancers, which are rare -were actually recurrences of the primary endometrial cancer. Moreover, the higher risk of second primary cancers within the first year of diagnosis suggests that some cancers were either present at diagnosis of the endometrial cancer or these second tumors developed rapidly after the endometrial cancer diagnosis.
If confirmed, our observations could benefit population health in several ways. First, given our observations of higher risk of obesity related cancers (eg, colorectal) following diagnosis of certain endometrial cancer subtypes, counseling regarding weight loss along with provision of resources to reduce barriers could be implemented. Epidemiological studies that test the impact of weight loss on second cancer risk will be important for creating an evidence base around this recommendation. In addition, our findings could be useful in the eventual development of evidence based guidelines aimed at early detection of second cancers among endometrial cancer survivors. For example, the consistently elevated risk of vaginal second primary cancer could prompt additional research on the efficacy of vaginal cancer screening modalities among endometrial cancer survivors.
In summary, our population based study of the relationship between endometrial cancer histological subtype and risk of subsequent malignancy in a US population revealed histology specific patterns. Furthermore, we confirmed increased risks of second primary cancers in specific anatomical sites regardless of histology. Although the exact etiology of second primary cancers after endometrial cancer is unknown, our data should prompt physician awareness of the development of second primary cancers in endometrial cancer survivors, particularly obesity related cancers.
